RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk – a focused healthcare company Investor presentation Full year 2025 2 Novo Nordisk® Investor presentation Full year 2025 Forward-looking statements Novo Nordisk's statutory Annual Report 2025, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the operating, financial an ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novo Nordisk expects sales and profits to shrink substantially in 2026 as competition from Eli Lilly and pricing pressure from the U.S. government chip away at its multibillion-dollar obesity drug business. The news delivered midday Tuesday shook investors and Wall Street analysts, sending Novo shares tumbling by double digits on stock exchanges in the U.S. a ...

>> IT'S 5:00 A. M. IN NEW YORK CITY.EQUITIES RESUMING THEIR SELLOFF DRIVEN BY STOCKS, ANTHROPIC TOPICS AI DISRUPTION. EARNINGS CONTINUE TO POUR IN. AMD FAILS TO IMPRESS INVESTORS.ALPHABET IS UP NEXT. IRAN ASKS THE U.S. TO MOVE THE UPCOMING TALKS FROM TURKEY TO OMAN AND FOCUS ON JUST THE NUCLEAR PROGRAM. LET'S LOOK AT HOW MARKETS ARE SETTING UP FOR THE DAY.YESTERDAY TURNED INTO A DOOM SELLING FOR EQUITIES EVEN IF IT DIDN'T LOOK LIKE THAT AT THE BEGINNING OF THE SESSION. -- INTO A DAY OF SELLING FOR EQUITIES, ...

Core Viewpoint - Novo Nordisk's CEO Mike Doustdar provided a pessimistic outlook on the company's prospects for 2026 during a media briefing following the pre-announcement of earnings [1] Group 1 - The company pre-announced its earnings a day prior to the media engagement [1] - CEO Mike Doustdar expressed concerns regarding the company's future performance [1]

Group 1 - The stock experienced a significant decline of 19% at the opening bell in Copenhagen [1] - The company's outlook for the upcoming year did not meet investor expectations, leading to the stock drop [1]

Novo Nordisk said Tuesday that fourth-quarter sales of Wegovy rose 17% on year. - Tom Little/Reuters Shares in Wegovy maker Novo Nordisk slid in early European trading Wednesday after guidance for the year ahead disappointed investors. In Copenhagen, the stock tumbled 19% at the opening bell after shares closed 15% lower in New York following Tuesday’s release of the company’s 2026 forecast. Most Read from The Wall Street Journal The Danish drugmaker said Tuesday that adjusted sales and operating profi ...

European shares edged lower on Wednesday, as shares of Novo Nordisk slumped after the weight-loss drugmaker issued a bleak forecast, while investors tracked software shares and awaited a key inflation report. ...

Good morning. This is Bloomberg Daybreak Europe. I'm sure a lot of research with your top stories.Software stocks sync a new tool from anthropic fuels Disruption fears wiping $285 billion from software, financial services and asset management shares. Meanwhile, Bitcoin falls to its lowest level since Donald Trump's election win. UBS reports a fourth quarter profit beats and reveals plans to buyback $3 billion of its own shares.We'll bring you our interview with the CEO, Sir Roger, later this morning. Plus, ...

Core Insights - Novo Nordisk's stock experienced an 18% drop following a surprise pre-release of its 2026 forecast, indicating a decline in sales and operating profit between 5% and 13%, which was worse than analysts' expectations [1][4] - CEO Mike Doustdar acknowledged the challenges posed by significantly lower U.S. pricing for its weight loss drug Wegovy, suggesting that a recovery may take time [2][6] - The company faces competition from cheaper alternatives and rivals like Eli Lilly, impacting its pricing strategy in the U.S. market [6][7] Financial Guidance - The guidance for 2026 indicates a decline in both sales and operating profit, which has led to significant market reactions, reminiscent of previous guidance cuts that resulted in sharp stock declines [4][8] - Analysts from Barclays noted that the current guidance might be overly conservative, similar to past instances where initial forecasts were not met [4] Market Dynamics - The launch of the Wegovy pill in the U.S. exceeded expectations, with 170,000 people using it within four weeks, showcasing strong initial demand despite pricing pressures [7] - The market is questioning whether the recovery will follow a "Nike swoosh" or a "U-shaped" pattern, indicating uncertainty about the timing and nature of the recovery [8]

Group 1 - Volvo Cars, based in Sweden, reported sales of 177,830 cars during the November-January period, reflecting a 7% decrease compared to the same period last year [1]